BenevolentAI Results Presentation Deck
Strategic validation: successful
collaboration with AstraZeneca
Multi-year Target-ID collaboration is delivering multiple,
novel targets for complex diseases with high unmet
need
Separate data environment established to integrate AstraZeneca's data
into a bespoke Knowledge Graph
BenevolentAl and AstraZeneca teams working in
close collaboration to explore, identify and validate targets
Deal structure of upfront license fee, milestone payments
and downstream royalties
Data generated via the collaboration enriches the
Benevolent Platform™
BenevolentAl Proprietary
AstraZeneca
Five novel targets selected
for AstraZeneca's portfolio
to date
2019
Initial deal focussed on
Chronic Kidney Disease &
Idiopathic Pulmonary Fibrosis
2022
3-year collaboration
expansion to include Heart
Failure & Systemic lupus
erythematosusView entire presentation